BRAF V600E mutation as a predictive factor of anti-EGFR monoclonal antibodies therapeutic effects in metastatic colorectal cancer: a meta-analysis / 中国医学科学杂志(英文版)
Chinese Medical Sciences Journal
;
(4): 197-203, 2014.
Article
in English
| WPRIM
| ID: wpr-242869
ABSTRACT
<p><b>OBJECTIVE</b>To investigate the correlation between BRAF V600E mutation and anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (MoAbs) therapeutic effects in metastatic colorectal cancer.</p><p><b>METHODS</b>Studies were included into meta-analysis to investigate the association between BRAF V600E mutation and clinical outcome in metastatic colorectal cancer patients treated with anti-EGFR MoAbs.</p><p><b>RESULTS</b>A total of 7 studies were included in this meta-analysis. The 7 studies included 1352 patients in total, sample sizes ranged from 67 to 493. Objective response rate (ORR), progression-free survival (PFS) and overall survival (OS) were collected from included studies and were used to assess the strength of the relation. In patients with wild-type KRAS, the pooled odds ratio for ORR of mutant BRAF over wild-type BRAF was 0.27 (95% CI=0.10-0.70). BRAF mutation predicted a deterioration in PFS and OS in wild-type KRAS patients treated with anti-EGFR MoAbs (hazard ratio=2.78, 95% CI=1.62-4.76; hazard ratio=2.54, 95% CI=1.93-3.32).</p><p><b>CONCLUSION</b>BRAF V600E mutation is related to lack of response and worse survival in wild-type KRAS metastatic colorectal cancer patients treated with anti-EGFR MoAbs.</p>
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Pathology
/
Colorectal Neoplasms
/
Proto-Oncogene Proteins B-raf
/
Allergy and Immunology
/
ErbB Receptors
/
Genetics
/
Antibodies, Monoclonal
/
Mutation
/
Neoplasm Metastasis
Type of study:
Prognostic study
/
Systematic reviews
Limits:
Humans
Language:
English
Journal:
Chinese Medical Sciences Journal
Year:
2014
Type:
Article
Similar
MEDLINE
...
LILACS
LIS